Efficacy and Safety of Vedolizumab Subcutaneously (SC) as Maintenance Therapy in Ulcerative Colitis

NCT02611830 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

383

Enrollment

INDUSTRY

Sponsor class

Conditions

Colitis, Ulcerative

Interventions

DRUG: Vedolizumab 300 mg IV
DRUG: Placebo IV
DRUG: Vedolizumab 108 mg SC
DRUG: Placebo SC

Sponsor

Takeda